Norpramin 10 mg/1
desipramine hydrochloride · TABLET, SUGAR COATED · Validus Pharmaceuticals LLC
Norpramin is a tablet, sugar coated containing desipramine hydrochloride at 10 mg/1, taken oral. Manufactured by Validus Pharmaceuticals LLC.
Key Facts
- Brand Name
- Norpramin
- Generic Name
- desipramine hydrochloride
- NDC Code (Product)
30698-007- Manufacturer
- Validus Pharmaceuticals LLC
- Strength
- 10 mg/1
- Dosage Form
- TABLET, SUGAR COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA014399
- Marketing Start
- 11/20/1964
Recall History
No Recall HistoryFull Prescribing Information
Indications & Usage
INDICATIONS AND USAGE NORPRAMIN is indicated for the treatment of depression.
Dosage & Administration
DOSAGE AND ADMINISTRATION Not recommended for use in children (see WARNINGS ). Lower dosages are recommended for elderly patients and adolescents. Lower dosages are also recommended for outpatients compared to hospitalized patients, who are closely supervised. Dosage should be initiated at a low level and increased according to clinical response and any evidence of intolerance. Following remission, maintenance medication may be required for a period of time and should be at the lowest dose that will maintain remission. Usual Adult Dose The usual adult dose is 100 mg to 200 mg per day. In more severely ill patients, dosage may be further increased gradually to 300 mg/day if necessary. Dosages above 300 mg/day are not recommended. Dosage should be initiated at a lower level and increased according to tolerance and clinical response. Treatment of patients requiring as much as 300 mg should generally be initiated in hospitals, where regular visits by the physician, skilled nursing care, and frequent electrocardiograms (ECGs) are available. The best available evidence of impending toxicity from very high doses of NORPRAMIN is prolongation of the QRS or QT intervals on the ECG. Prolongat…
Warnings
WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (selective serotonin re-uptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressant…
Contraindications
CONTRAINDICATIONS The use of MAOIs intended to treat psychiatric disorders with NORPRAMIN or within 14 days of stopping treatment with NORPRAMIN is contraindicated because of an increased risk of serotonin syndrome. The use of NORPRAMIN within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting NORPRAMIN in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ). NORPRAMIN is contraindicated in the acute recovery period following myocardial infarction. It should not be used in those who have shown prior hypersensitivity to the drug. Cross-sensitivity between this and other dibenzazepines is a possibility.
Drug Interactions
Drug Interactions Drugs Metabolized by P450 2D6. The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhy…
Adverse Reactions
ADVERSE REACTIONS Included in the following listing are a few adverse reactions that have not been reported with this specific drug. However, the pharmacologic similarities among the tricyclic antidepressant drugs require that each of the reactions be considered when NORPRAMIN is given. Cardiovascular: Hypotension, hypertension, palpitations, heart block, myocardial infarction, stroke, arrhythmias, premature ventricular contractions, tachycardia, ventricular tachycardia, ventricular fibrillation, sudden death There has been a report of an "acute collapse" and "sudden death" in an 8-year-old (18 kg) male, treated for 2 years for hyperactivity. There have been additional reports of sudden death in children (see PRECAUTIONS-Pediatric Use ). Psychiatric: Confusional states (especially in the elderly) with hallucinations, disorientation, delusions; anxiety, restlessness, agitation; insomnia and nightmares; hypomania; exacerbation of psychosis Neurologic: Numbness, tingling, paresthesias of extremities; incoordination, ataxia, tremors; peripheral neuropathy; extrapyramidal symptoms; seizures; alterations in EEG patterns; tinnitus Symptoms attributed to Neuroleptic Malignant Syndrome have…
Frequently Asked Questions
What is Norpramin used for?
Norpramin contains desipramine hydrochloride. It is a tablet, sugar coated taken oral. Consult your doctor for specific uses.
Is Norpramin a controlled substance?
Norpramin is not classified as a controlled substance by the DEA.
What is the generic name for Norpramin?
The generic name for Norpramin is desipramine hydrochloride. There are 11 other brand versions of desipramine hydrochloride.
What is the NDC code for Norpramin 10 mg/1?
The NDC (National Drug Code) for Norpramin 10 mg/1 is 30698-007, listed by Validus Pharmaceuticals LLC.
Other Norpramin Dosages
Other Desipramine Brands
See all →- Desipramine Hydrochloride10 mg/162135-593
- DESIPRAMINE HYDROCHLORIDE50 mg/162332-317
- DESIPRAMINE HYDROCHLORIDE10 mg/123155-578
- DESIPRAMINE HYDROCHLORIDE100 mg/146708-319
- DESIPRAMINE HYDROCHLORIDE75 mg/150742-115
- Desipramine Hydrochloride75 mg/162135-597
- DESIPRAMINE HYDROCHLORIDE100 mg/162332-319
- DESIPRAMINE HYDROCHLORIDE150 mg/162332-320
- DESIPRAMINE HYDROCHLORIDE10 mg/146708-315
- DESIPRAMINE HYDROCHLORIDE10 mg/162332-315
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)